Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers

PHASE3CompletedINTERVENTIONAL
Enrollment

203

Participants

Timeline

Start Date

June 27, 2014

Primary Completion Date

July 4, 2017

Study Completion Date

July 4, 2017

Conditions
Hereditary Periodic Fevers
Interventions
DRUG

Canakinumab

Canakinumab solution for subcutaneous injection in vial which contained 150mg/mL canakinumab in 1 mL solution.

DRUG

Placebo

Matching placebo to canakinumab solution for subcutaneous injection

Trial Locations (65)

1011

Novartis Investigative Site, Lausanne

1023

Novartis Investigative Site, Budapest

1094

Novartis Investigative Site, Budapest

1200

Novartis Investigative Site, Brussels

2650

Novartis Investigative Site, Edegem

3000

Novartis Investigative Site, Leuven

3500

Novartis Investigative Site, Hasselt

4000

Novartis Investigative Site, Liège

10117

Novartis Investigative Site, Berlin

13353

Novartis Investigative Site, Berlin

16147

Novartis Investigative Site, Genova

20246

Novartis Investigative Site, Hamburg

22081

Novartis Investigative Site, Hamburg

25123

Novartis Investigative Site, Brescia

27100

Novartis Investigative Site, Pavia

28034

Novartis Investigative Site, Madrid

28046

Novartis Investigative Site, Madrid

30029

Novartis Investigative Site, Nîmes

30120

Novartis Investigative Site, El Palmar

34093

Novartis Investigative Site, Istanbul

34098

Novartis Investigative Site, Istanbul

34137

Novartis Investigative Site, Trieste

44195

Novartis Investigative Site, Cleveland

45147

Novartis Investigative Site, Essen

46026

Novartis Investigative Site, Valencia

48109

Novartis Investigative Site, Ann Arbor

49202

Novartis Investigative Site, Petah Tikva

50139

Novartis Investigative Site, Florence

53757

Novartis Investigative Site, Saint Augustin

69677

Novartis Investigative Site, Bron

72076

Novartis Investigative Site, Tübingen

75015

Novartis Investigative Site, Paris

80131

Novartis Investigative Site, Napoli

80337

Novartis Investigative Site, München

82110

Novartis Investigative Site, Germering

90027

Novartis Investigative Site, Los Angeles

92019

Novartis Investigative Site, Sciacca

94275

Novartis Investigative Site, Le Kremlin-Bicêtre

98125

Novartis Investigative Site, Messina

115522

Novartis Investigative Site, Moscow

117198

Novartis Investigative Site, Moscow

119991

Novartis Investigative Site, Moscow

194100

Novartis Investigative Site, Saint Petersburg

344022

Novartis Investigative Site, Rostov-on-Don

3339419

Novartis Investigative Site, Haifa

3525408

Novartis Investigative Site, Haifa

5266202

Novartis Investigative Site, Ramat Gan

9103102

Novartis Investigative Site, Jerusalem

T3B 6A8

Novartis Investigative Site, Calgary

V6H 3V4

Novartis Investigative Site, Vancouver

Unknown

Novartis Investigative Site, Galway

00165

Novartis Investigative Site, Roma

00168

Novartis Investigative Site, Roma

812-8582

Novartis Investigative Site, Fukuoka

236-0004

Novartis Investigative Site, Yokohama

606 8507

Novartis Investigative Site, Sakyo-ku

951-8520

Novartis Investigative Site, Niigata

6500 HB

Novartis Investigative Site, Nijmegen

3508 GA

Novartis Investigative Site, Utrecht

08950

Novartis Investigative Site, Esplugues de Llobregat

08035

Novartis Investigative Site, Barcelona

06100

Novartis Investigative Site, Ankara

LS9 7TF

Novartis Investigative Site, Leeds

NW3 2QG

Novartis Investigative Site, London

WC1N 1EH

Novartis Investigative Site, London

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY